Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder

被引:4
|
作者
Hirjak, Dusan [1 ]
Hochlehnert, Achim [2 ]
Thomann, Philipp Arthur [1 ]
Kubera, Katharina Maria [1 ]
Schnell, Knut [1 ]
机构
[1] Heidelberg Univ, Dept Gen Psychiat, Ctr Psychosocial Med, Heidelberg, Germany
[2] Heidelberg Univ, Dept Gen Internal Med & Psychosomat, Ctr Psychosocial Med, Heidelberg, Germany
来源
PLOS ONE | 2016年 / 11卷 / 07期
关键词
BIPOLAR DISORDER; NEGATIVE SYMPTOMS; SYSTEM; CARE; POPULATION; PSYCHIATRY; DIAGNOSIS; STABILITY; VOLUME;
D O I
10.1371/journal.pone.0157635
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Schizophrenia spectrum disorders result in enormous individual suffering and financial burden on patients and on society. In Germany, there are about 1,000,000 individuals suffering from schizophrenia (SZ) or schizoaffective disorder (SAD), a combination of psychotic and affective symptoms. Given the heterogeneous nature of these syndromes, one may assume that there is a difference in treatment costs among patients with paranoid SZ and SAD. However, the current the national system of cost accounting in psychiatry and psychosomatics in Germany assesses all schizophrenia spectrum disorders within one category. Methods The study comprised a retrospective audit of data from 118 patients diagnosed with paranoid SZ (F20.0) and 71 patients with SAD (F25). We used the mean total costs as well as partial cost, i.e., mean costs for medication products, mean personal costs and mean infrastructure costs from each patient for the statistical analysis. We tested for differences in the four variables between SZ and SAD patients using ANCOVA and confirmed the results with bootstrapping. Results SAD patients had a longer duration of stay than patients with SZ (p = .02). Mean total costs were significantly higher for SAD patients (p = .023). Further, we found a significant difference in mean personnel costs (p = .02) between patients with SZ and SAD. However, we found no significant differences in mean pharmaceutical costs (p = .12) but a marginal difference of mean infrastructure costs (p = .05) between SZ and SAD. We found neither a common decrease of costs over time nor a differential decrease in SZ and SAD. Conclusion We found evidence for a difference of case related costs of inpatient treatments for paranoid SZ and SAD. The differences in mean total costs seem to be primarily related to the mean personnel costs in patients with paranoid SZ and SAD rather than mean pharmaceutical costs, possibly due to higher personnel effort and infrastructure.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable?
    Heinrichs, R. Walter
    Ammari, Narmeen
    Vaz, Stephanie McDermid
    Miles, Ashley A.
    [J]. SCHIZOPHRENIA RESEARCH, 2008, 99 (1-3) : 149 - 154
  • [2] Paranoid Schizophrenia versus Schizoaffective Disorder: Neuropsychological Aspects
    Leposavic, Ljubica
    Leposavic, Ivana
    Saula-Marojevic, Biljana
    Gavrilovic, Predrag
    [J]. SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2015, 143 (7-8) : 391 - 396
  • [3] Evidence for Distinguishable Treatment Costs Among ICD-10 Schizophrenia Spectrum Disorders Subtypes
    Hirjak, Dusan
    Hochlehnert, Achim
    Schnell, Knut
    [J]. JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2015, 18 : S20 - S20
  • [4] Could schizoaffective disorder, schizophrenia and bipolar I disorder be distinguishable using cognitive profiles?
    Chen Chih-Ken
    Lee Chun-Yi
    Lee Yu
    Hung Chi-Fu
    Huang Yu-Chi
    Lee Sheng-Yu
    Huang Ming-Chyi
    Chong Mian-Yoon
    Chen Yi-Chih
    Wang Liang-Jen
    [J]. PSYCHIATRY RESEARCH, 2018, 266 : 79 - 84
  • [5] Treatment Patterns for Schizoaffective Disorder and Schizophrenia Among Medicaid Patients
    Olfson, Mark
    Marcus, Steven C.
    Wan, George J.
    [J]. PSYCHIATRIC SERVICES, 2009, 60 (02) : 210 - 216
  • [6] EXPANDED TREATMENT OPTIONS FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER: EVIDENCE FROM 15 BIOMARKERS
    Fryar-Williams, S.
    Saunders, N.
    Mack, M.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2015, 49 : 55 - 55
  • [7] Treatment of schizoaffective disorder and schizophrenia with mood symptoms
    Levinson, DF
    Umapathy, C
    Musthaq, M
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1999, 156 (08): : 1138 - 1148
  • [9] Comparative analysis of the neurocognitive profile of patients with a first episode of paranoid schizophrenia and schizoaffective disorder
    Zaytseva, Y.
    Gurovich, I. Y.
    Sarkisyan, G.
    Sarkisyan, V.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S348 - S348
  • [10] EVIDENCE OF NEUROPHYSIOLOGICAL DISTINCTION BETWEEN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
    Zaytseva, Y.
    Garakh, Z.
    Kapranova, A.
    Gurovich, I. Y.
    Strelets, V. B.
    [J]. EUROPEAN PSYCHIATRY, 2013, 28